Skip to product information
1 of 3

IL-4 Protein, Rat

IL-4 Protein, Rat

Catalog Number: UA040374 Brand: UA BIOSCIENCE
Price:
Regular price $250 USD
Regular price Sale price $250 USD
Size:

For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details

Product Details

Product Specification


Species Rat
Accession P20096
Amino Acid Sequence His23-Ser147
Expression System E.coli
Molecular Weight

14 kDa (Reducing)

Purity >95% by SDS-PAGE and HPLC.
Endotoxin <0.1EU/μg
Conjugation Unconjugated
Tag No Tag
Physical Appearance Lyophilized Powder
Storage Buffer 20mM Tris, 150mM NaCl, pH8.0
Reconstitution

Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.

Stability & Storage

·12 months from date of receipt, lyophilized powder stored at -20 to -80℃.
·3 months, -20 to -80℃ under sterile conditions after reconstitution.
·1 week, 2 to 8℃ under sterile conditions after reconstitution.
·Please avoid repeated freeze-thaw cycles.

Reference

J Neuropathol Exp Neurol. 2016 Nov 1;75(11):1058-1071.

Background

IL-4 is a key regulator in hormone control and adaptive immunity. It is a compact globular protein structure stabilized by three disulphide bonds, forming a four alpha-helix bundle with a left-handed twist and a 2-stranded anti-parallel beta sheet. In rats, IL-4 shares sequence identities with other species, which indicates its conserved role across different mammals. In the industrial sector, IL-4 and its related pathways are of significant interest, particularly in the development of therapeutics for autoimmune diseases, cancer, psoriasis, and arthritis. IL-4 has been applied in the treatment of autoimmune disorders like multiple myeloma, and it is also used to inhibit the detrimental effects of Th1 cells. Furthermore, IL-4 has been shown to promote the growth of epithelial tumors by mediating increased proliferation and survival, which has implications in cancer research and treatment.

Picture

Bioactivity

Determined by its ability to stimulate proliferation of TF-1 cells. The expected EC50 is less than 30ng/ml.

SDS-PAGE

2μg (R: reducing condition, N: non-reducing condition).

RP-HPLC

>95% as determined by RP-HPLC.